HIV Drug Market to Touch $26.46 Billion

Global HIV Drug Market was valued at $20,448 million in 2015 and is expected to garner $26,458 million by 2022, registering a CAGR of 3.7% during the forecast period 2016-2022. Human immunodeficiency virus (HIV) is one of the most infectious diseases with around 36.7 million people suffering by the end of 2015, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS).

The major factors that boost the HIV drug market growth include increase in prevalence of HIV and rise in treatment & diagnosis rate. Moreover, there is an increase in the government initiative to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth. Thus, rise in awareness through such government initiatives are also expected to drive the HIV drugs market. However, stringent government regulations for the approval and commercialization of HIV drugs is expected to restrain the industry growth.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/1867

North America and Europe are expected to dominate the global HIV drug market during the forecast period, while emerging countries in Asia-Pacific and Latin America are expected to offer significant growth opportunities.

Increase in Number of HIV Infected Patients Worldwide

According to WHO, 36.7 million people were diagnosed with HIV/AIDS in 2015, whereas, 1.1 million people died of AIDS-related illness in the same year. The world has very high prevalence of people living with HIV owing to the various factors, such as lack of availability of medication for the treatment of HIV infection. In the emerging nations including  sub-Saharan Africa, countries with low income do not have sufficient funds to buy high price drugs leading to increase in the population living with HIV.

Multi-class combination drugs segment had accounted for more than one-third revenue of the overall HIV drug market in 2015, owing to increase in adoption of combination drugs from this medication class due to their better results in the control of HIV & related coinfections and their ease in consumption & adherence. Increase in the number of HIV infected patients across the globe increases the need for effective treatment for HIV related diseases. Use of Multi-class combination products is an efficient way of treating HIV. Atripla and Prezista are among the blockbuster combination drugs used in the HIV treatment.

Human immunodeficiency virus (HIV) had affected around 36.7 million globally by the end of 2015, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS). Antiretroviral Therapy (ART) drugs are used for the treatment of HIV.

Geographically, North America and Europe market hold larger share in the HIV drugs market due to high HIV infected population, well-established healthcare systems in these regions leading to higher diagnosis & treatment rate, and the presence of top pharmaceutical companies in the region. The Asia-Pacific market offers lucrative growth opportunity due to increase in demand for advanced health care services in the emerging economies (such as India and China) and increase in prevalence of HIV infected population coupled with rise in government initiatives to control the spread of HIV in these nations. Thus, the emerging markets have a huge potential for the market growth in the HIV drug market.

Get More Details @ https://www.alliedmarketresearch.com/connect-to-analyst/1867

The major factors that boost the HIV drug market growth include increase in prevalence of HIV and rise in treatment & diagnosis rate. Moreover, there is an increase in the government initiative to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth. Thus, rise in awareness through such government initiatives are also expected to drive the HIV drugs market. However, stringent government regulations for the approval and commercialization of HIV drugs is expected to restrain the industry growth.

The major companies profiled in the report include 

• Boehringer Ingelheim International GmbH, 

• Merck & Co., Inc., 

• ViiV Healthcare, 

• AbbVie, 

• F. Hoffmann-La Roche Ltd., 

• Teva Pharmaceutical Industries Ltd., 

• Bristol-Myers Squibb, 

• Gilead Sciences, Inc., 

• Johnson & Johnson, and 

• Cipla Limited.

Table Of Content

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION

1.2. KEY BENEFITS

1.3. KEY MARKET SEGMENTS

1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE

3.2. KEY FINDINGS

3.2.1. Top investment pockets

3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS

3.4. PRODUCT PIPELINE ANALYSIS

3.5. MARKET DYNAMICS

HIV Drug Market: https://www.alliedmarketresearch.com/press-release/hiv-drugs-market.html

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at contact@wiredrelease.com.